Exhibition Review丨Tongteng Ruijie Shines: QbD Biopharmaceuticals Quality Science Conference Witnesses the Power of Innovation

Release date:2024-08-01



On 27th July 2024, the 5th QbD Biopharmaceutical Quality Science Conference was successfully concluded in Beijing. With the theme of ‘Innovation Breaks the Circumstances, “Quality” Must Be Done’, the conference gathered more than 70 domestic and foreign well-known pharmaceutical companies, contract service leaders, The conference, with the theme of ‘Innovation Breaks the Game, “Quality” is the Way to Go’, brought together more than 70 domestic and international leaders from well-known pharmaceutical companies, leading contract service companies, institutions and colleges in the biopharmaceutical industry to explore the innovative development path of the quality of biopharmaceuticals in China, with the aim of helping enterprises improve the quality of pharmaceuticals and quality management systems, so as to achieve convergence with international standards.










In this grand event of the biopharmaceutical industry, Tongteng Ruijie brought its popular products to Booth A25 and became the focus of attention of the whole venue, including CEL-G® Culture Ad60 series fixed-bed bioreactors, Refeyn TwoMP single-molecule mass analysis system, WOLF G2 single-cell flexible sorting system, helixcyto native molecule interaction cell analysis system, each of which attracted many experts and scholars and industry colleagues to visit and highly appraised with its unique innovative features and excellent performance. analysis system, each product with its unique innovative features and excellent performance, attracted many experts and scholars and industry colleagues stopped to visit and highly evaluated.


5

Exhibition Scene


Among them, the CEL-G®Culture Ad60 series of fixed-bed bioreactors, with its high efficiency and stability, provides a solid support for the biopharmaceutical process, demonstrating the deep knowledge of Tongteng Xinchuang, a wholly-owned subsidiary of Tongteng Biological, in bioprocess development. Meanwhile, Refeyn's TwoMP single-molecule mass analysis system, with its unparalleled precision, is not only regarded as the most sensitive, easy-to-use and efficient molecular measurement tool in the field of biomolecule detection, but also leads the technological revolution. Another product, the Refeyn SamuxMP Single Molecule Mass Analyser, shines in AAV (Adeno-associated virus) vector research. Tailored for AAV research, development and production, this analyser can accurately quantify the empty/solid ratio of various serotypes of AAV vectors in a very short period of time, greatly simplifying the operation process by requiring only a small amount of low-concentration samples and minimal sample preparation, which provides unprecedented convenience and high efficiency in the in-depth characterisation and quality control of AAV vectors, and further promotes the rapid development of the fields of biopharmaceuticals and gene therapies. It further promotes the rapid development of biopharmaceutical and gene therapy fields.



The debut of the WOLF G2 single-cell flexible sorting system has opened a new chapter in cell research with its flexible and efficient characteristics. Meanwhile, the helixcytonative molecular interaction cell analysis system, with its unique technological advantages, delves into the mysteries at the cellular level, providing a powerful tool for life science research.




The attendees highly praised the products of Tongteng Ruijie, believing that these products not only demonstrate Tongteng Ruijie's strength in the industry, but also indicate the huge potential and broad prospects of the domestic biopharmaceutical industry in quality control and technological innovation.


On this occasion, Tongteng Ruijie not only demonstrated its own innovative achievements, but also injected new vitality into the development of the domestic biopharmaceutical industry, and stimulated people's infinite expectations for the future improvement of the quality of domestic biopharmaceuticals.